ライフサイエンスコーパス: diethylcarbamazine

1 tions (albendazole plus either ivermectin or diethylcarbamazine).

2 10 patients treated for onchocerciasis with diethylcarbamazine.

3 s also a site of action of the anthelmintic, diethylcarbamazine.

4 ted that Brugia malayi TRP-2 is activated by diethylcarbamazine.

5 le oral dose of IDA (ivermectin, 200 mug/kg; diethylcarbamazine, 6 mg/kg; plus albendazole, a fixed d

6 Recent studies, have found that diethylcarbamazine acts on the muscle of adult female Br

7 s with a low (5%) baseline mf prevalence and diethylcarbamazine + albendazole (DA) or ivermectin + di

8 rbamazine + albendazole (DA) or ivermectin + diethylcarbamazine + albendazole (IDA) treatment, elimin

9 ears of mass drug administration (MDA) using diethylcarbamazine and albendazole (DA).

10 dose, triple-drug treatment (ivermectin with diethylcarbamazine and albendazole [IDA]) is superior to

11 All groups also received diethylcarbamazine and albendazole for lymphatic filaria

12 alence than anticipated, and the addition of diethylcarbamazine and albendazole to scabies treatment.

13 er antifilariasis drugs, namely doxycycline, diethylcarbamazine and albendazole, intradermally.

14 nellosis experienced treatment failure (with diethylcarbamazine and levamisole-mebendazole, respectiv

15 hat the triple-drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) is much more e

16 e dose of a triple-drug regimen (ivermectin, diethylcarbamazine, and albendazole) has been shown to c

17 nologic perturbations nor on the efficacy of diethylcarbamazine as a curative agent in loiasis.

18 Diethylcarbamazine citrate (DEC) treatment of loiasis is

19 is, topical application of the anthelminthic diethylcarbamazine (DEC) induces clinical and histologic

20 Diethylcarbamazine (DEC) is used to treat lymphatic fila

21 Treatment of onchocerciasis with diethylcarbamazine (DEC) or ivermectin is associated wit

22 became undetectable within 1 month following diethylcarbamazine (DEC) treatment and remained negative

23 riple-drug therapy of the antifilarial drugs diethylcarbamazine (DEC), ivermectin (IVM), and albendaz

24 s with Loa loa infection treated with either diethylcarbamazine (DEC), the drug of choice for loiasis

25 Diethylcarbamazine (DEC)-medicated salt may overcome the

26 before and after administration of 300 mg of diethylcarbamazine (DEC).

27 ian patients before and after treatment with diethylcarbamazine for Brugia malayi infection, and reco

28 the newly approved ivermectin, albendazole, diethylcarbamazine (IDA) regime for Lymphatic Filariasis

29 Diethylcarbamazine is a classic anthelmintic that is use

30 The mode of action of diethylcarbamazine is still not well understood with the

31 Drugs to treat filariasis include diethylcarbamazine, ivermectin, and albendazole, which a

32 lipoxygenase inhibition was performed using diethylcarbamazine or the 5-lipoxygenase activating-prot

33 IDA]) is superior to a two-drug combination (diethylcarbamazine plus albendazole [DA]) that is widely

34 ngle co-administered dose of ivermectin plus diethylcarbamazine plus albendazole [IDA] is noninferior

35 f a new triple drug regimen (ivermectin plus diethylcarbamazine plus albendazole, IDA) is non-inferio

36 Our study shows that diethylcarbamazine's action is dependent upon the Brugia

37 Albendazole plus diethylcarbamazine significantly reduced prevalence of e

38 s and declined (but did not disappear) after diethylcarbamazine therapy in infected patients.

39 Application of diethylcarbamazine to Bma-trp-2b transfected HEK293 cell

40 was positive for Wolbachia DNA 4-48 h after diethylcarbamazine treatment.

41 ds nor apheresis reduced the efficacy of the diethylcarbamazine used to treat these subjects.